Samuel Kareff, MD, MPH

Thanks again @IASLC and all #LALCA23 organizers and faculty! #LCSM

Happy to share our work on TEM8, in collaboration with @carisls. @SamuelKareffMD, our former Chief Fellow, did an excellent job exploring TEM8 in neuroendocrine neoplasms. We’re now handing the baton to our current @umiamimedicine Chief Fellow, @Jani_Chinmay, who is prospectively evaluating TEM8 within our ongoing SVV-001 Phase 1 study. It’s always encouraging to see emerging investigators pursue research in neuroendocrine oncology—a field with significant knowledge gaps and immense opportunity for impact. @NANETS1

Excited to share our publication led by @SamuelKareffMD exploring the genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1)🧬🔬TEM8 is a tumor endothelial marker linked to angiogenesis and immune interactions within TME. It is also an emerging therapeutic target, including oncolytic viral strategies such as SVV-001 🎯🦠Importantly, a Phase 1 trial evaluating SVV-001 with Ipi/Nivo is ongoing at @SylvesterCancer. 🏥🌴@AmanChauhanMD @GlopesMd @PeterHoseinMD @DanielSumarriva @HemOncMiami @carisls #Oncology #PrecisionMedicine #CancerResearch #SCLC sciencedirect.com/science/articl…

IMHOTEP just gave us something we’ve been looking for in MSI-H colon cancer: prospective single-agent PD-1 data in the localized setting. And honestly… this is great. 🧬 Because the field now looks like this: • NICHE-1 / NICHE-2 → dual IO, pCR ~60–67% in colon (and no recurrences) • Dostarlimab nonoperative rectal cancer study → single-agent PD-1, opening the NOM conversation Now IMHOTEP (pembro alone 1-2 cycles neoadjuvant and 1 year afterward): • pCR: 53% overall • 1 cycle: 46% • 2 cycles: 68% • Median follow-up ~24 months • Only 3 recurrences 👀 ~70% pCR with just two doses of pembrolizumab is impressive. But what stands out is the follow-up. At ~2 years, 3 recurrences. Now compare: NICHE-2 (nivo + ipi 2 cycles neoadjuvant) • pCR ~67% • Near-universal response rates • No recurrences IMHOTEP (pembro 2 cycles neoadjuvant + 1 year after) • pCR ~68% (with 2 cycles) • Low early recurrence signal Questions I'm pondering: Is that additional year of single agent worth it? Should we be offering nonoperative management or using a neoadjuvant playbook (100% DFS is incredibly). 🤔 Wondering what other people are doing for these patients today... ascopubs.org/doi/10.1200/JC… @OncoAlert @Onco_Nexus @TheGutOncLab @OncBrothers

What does it take to improve #lungcancer outcomes worldwide? In this episode of Lung Cancer Considered, @StephenVLiu , @AndreasC466 , @SamuelKareffMD , & Nicole Rankin discuss global policy strategies, from early detection to access, workforce capacity, and survivorship. 🎧 bit.ly/47hQfFX #LungCancerConsidered

1/n Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJM nejm.org/doi/full/10.10… A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.

Honored to share I matched @HopkinsMedicine! Today is also my Mom’s birthday. She passed in 2023 after a 6-year battle with DLBCL. Her fight drives my passion for patient care, cancer research, and health equity. I’m excited to train at Hopkins to continue this work! #Match2026

On the next episode of the @IASLC podcast, Lung Cancer Considered, I sit down with members of the Global Policy and Partnerships Committee to learn how policy impacts lung cancer research, treatment, and prevention. Thanks to Drs. @AndreasC466 @SamuelKareffMD @nicole_rankin8n!

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies In >13,000 tumors, MTAP deletion was found in: ALK 27–45% RET 18–35% EGFR 17–29% 98% co-deleted with CDKN2A. TKI outcomes unchanged ⚠️⚠️ annalsofoncology.org/article/S0923-… #NSCLC #lcsm #EGFR

Discussing IASLC Global Policy Objectives on Lung Cancer Considered - Samuel Kareff @IASLC @SamuelKareffMD oncodaily.com/voices/samuel-… #OncoDaily #Oncology #Cancer #Health #Medicine #LungCancer #MedX #MedTwitter

Truly a pleasure to discuss @IASLC #GlobalPolicy on #LungCancerConsidered hosted by former attending @StephenVLiu! It takes a village to move such agenda forward. Take a listen alongside @AndreasCharal and #NicoleRankin here podcasts.apple.com/us/podcast/lun…

Nice collaboration among Five institutions in Miami @MCIStrong @mhshospital @SylvesterCancer @mtsinaimiami @BaptistHealthSF @OncologyInst and @GuardantHealth studying germline in Hispanic #lungcancer patients #lcsm @FLASCO_ORG @Latinamd @MikeCusnir @SamuelKareffMD @EddieSantosMD @ShivaniDalalMD

In our recent study, we evaluated the cost-effectiveness of durvalumab following chemoradiation in limited-stage SCLC. While survival gains are meaningful, our analysis highlights the importance of integrating value-based decision-making as new standards of care emerge. As oncology continues to advance rapidly, incorporating health-economic analyses alongside efficacy data is essential to ensure equitable and sustainable access for patients.
#HealthEconomics #LungCancer #Immunotherapy @GlopesMd @SylvesterCancer @HemOncMiami @SamuelKareffMD @maysswarya news.med.miami.edu/durvalumab-off…

Is it sexy? No. Is it incredibly important for how we treat patients? Absolutely 🧠🧬 For over 20 years, 6 months of oxaliplatin plus a fluoropyrimidine has been the default for stage III colon cancer, and often high-risk stage II and rectal cancer. The cost has always been cumulative neuropathy that can follow patients for life ⚡️🖐️ The SCOT trial, the largest study in the IDEA collaboration, gives us long-term clarity with nearly 6,100 patients and more than 6 years of follow-up: 📊 5-yr DFS identical with 3 vs 6 months: 72.9% vs 72.9% 📈 5-yr OS identical: 82.4% vs 82.4% ✅ Noninferiority for OS formally met for 3 months Where this really matters clinically: 🟢 CAPOX clearly supports 3 months 🟢 Low-risk stage III shows no OS penalty 🟡 Even high-risk disease sees only tiny absolute OS differences ⚠️ Meanwhile, neuropathy nearly doubles when oxaliplatin is extended to 6 months. Many patients pay a lifelong price for minimal benefit. SCOT also uniquely included rectal cancer patients treated with upfront surgery, and here too, 3 months held up. This fits perfectly with modern TNT strategies 🧩 Takeaway: This isn’t flashy, but it’s foundational. For most patients with localized colon or rectal cancer, 3 months of adjuvant CAPOX is enough. Six months should be the exception, not the rule, and always a shared decision 🤝 Sometimes the most important advance is knowing when to stop. @OncoAlert @TheGutOncLab #GI26 ascopubs.org/doi/pdf/10.120…

In our new paper in @JCOGO_ASCO , we evaluate the cost-effectiveness of durvalumab consolidation for limited-stage #SCLC in the US. While durvalumab improves survival, ICERs exceeded willingness-to-pay thresholds, with patients who developed extrathoracic progression showing more favorable cost-effectiveness estimates. @SylvesterCancer @GlopesMd @maysswarya @SamuelKareffMD @HemOncMiami 🔗ascopubs.org/doi/10.1200/GO…

I have published more than 300 articles over the last 25+ years but this was a first for me: opinion piece/letter at the @WSJ thank you for taking it - “The market for medications is imperfect. We grant patents and exclusivity to reward innovation, recognizing the risk and investment involved in drug development. But the same system creates temporary monopolies, and without mechanisms to ensure post-exclusivity competition or value-based pricing, access suffers. Balancing innovation with affordability isn’t antimarket—it is what keeps the market functional and socially sustainable.” @SylvesterCancer @uicc @IASLC @asco @myESMO @Jani_Chinmay @Latinamd @COlazagasti

Delighted to bring #PrecisionOncology to all patients at @BaptistHealthSF #LynnCancerInstitute by rebooting this ground-breaking #MolecularTumorBoard Thanks to all involved including co-host @Sarbaji85064063, @BRRH_Foundation leaders and @carisls collaborators!

The FRONT-BRAF study, investigating the optimal 1st-line treatment for patients w/ stage IV BRAF V600E-mut NSCLC, has just been published in @TheLancetOncol thelancet.com/journals/lanon… This is a global effort involving 17 major cancer centres across Italy, USA, France, & Brazil. 1/9

Current @NCCN guidelines for germline testing. This is one place where we collectively need to do better not only to ensure we have the discussion for Rx options but this has profound impact on pts family! #OncTwitter #MedTwitter #MedEd #bcsm #lcsm #gusm #gism

Adjuvant therapy in colon cancer has come a long way. FOLFOX and capecitabine remain the backbone, but a series of trials highlight how we can go beyond “chemo as usual” to improve both tolerability and efficacy: 🧬 ALASCCA – In stage II–III CRC with PI3K pathway mutations, daily aspirin (160 mg) cut recurrence risk by ~50% (HR 0.49). 🖐 D-TORCH – Topical diclofenac gel reduced grade ≥2 hand-foot syndrome from 15% → 3.8% at 12 weeks, keeping more patients on full-dose capecitabine. 💊 B12 – Methylcobalamin supplementation lowered the rate of clinically significant HFS (BMJ 2025), a low-cost and safe toxicity-mitigation strategy. 🏃 CHALLENGE – Structured exercise after adjuvant therapy lowered recurrence/new primary risk by 28% and death by 37% over long-term follow-up. These studies point to a bigger picture: adjuvant therapy isn’t just about getting through chemo. It’s about layering strategies that make treatment more tolerable while meaningfully boosting outcomes. What else should we be adding to the adjuvant colon cancer playbook (no more bolus 5-FU)? @TheGutOncLab @OncoAlert @OncBrothers

It was an honor to share the stage with colleagues from Ireland, India, Japan, Austria, and South Africa discussing workforce challenges, resource limitations, and expanding access to care globally in our #GlobalPolicyandPartnerships session

Reflecting on a data-packed @IASLC #WCL25 with non-clinical panels on Narrowing Disparities in Effective Management of Lung Cancer on the Global Scale and the @WHO #IntegratedLungHealthResolution stand out most--time to bring these findings home!